Background/objectives: Non-small cell lung cancer and pleural mesothelioma are among the most lethal and therapy-resistant tumors in humans. These tumors are diagnosed late, frequently present pleural effusion and develop drug resistance, and the treatment is often inefficient and largely alliative. Therefore, there is an urgent need to refine the selection of drugs and patients for personalized treatment.Methods: To progress the field, we performed a systematic literature review in line with the PRISMA guidelines followed by a narrative synthesis approach to identify themes.Results: The literature to date shows, in general, a positive correlation between the drug-sensitivity of patient-derived cells ex vivo and the clinical outcome. However, only a handful of these studies show a numerical correlation. This, along with the vast diversity of correlated techniques and parameters makes it difficult to directly compare the findings. To build a common knowledge base for future studies, we therefore offer a comprehensive summary of the literature, identify gaps, and suggest future avenues for research.Conclusions: We present unified recommendations for the collection, preparation, and ex vivo sensitivity testing of samples for the future development of personalized medicine.
背景/目的：非小细胞肺癌与胸膜间皮瘤是人类致死率最高且治疗耐受性最强的肿瘤类型。这类肿瘤通常确诊较晚，常伴有胸腔积液并产生耐药性，现有治疗手段往往效果有限且以姑息疗法为主。因此，亟需优化药物与患者的匹配筛选机制以实现个体化治疗。 方法：为推进该领域发展，我们依据PRISMA指南开展系统性文献综述，并采用叙述性综合方法进行主题归纳。 结果：现有文献普遍显示患者来源细胞的离体药物敏感性与临床疗效呈正相关，但仅少数研究呈现量化相关性。加之相关检测技术与参数存在巨大差异，导致研究结果难以直接比较。为此，我们通过系统性文献梳理构建未来研究的共同知识基础，明确当前研究空白并提出后续研究方向。 结论：我们为个体化医疗的未来发展提出关于样本采集、制备及离体敏感性检测的统一标准化建议。
肿瘤(癌症)患者之家